Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Characterizing Environmental Adaption and Virulence of Gut Microbiome Enterococcus Spp. from Patients Receiving CD19-Targeted CAR-T Cell Therapy

Niklas Deschl, Viktoria Blumenberg, Maria-Luisa Schubert, Anita Schmitt, Michael Schmitt, Marion Subklewe, Christoph Stein-Thoeringer

Blood (2024) 144 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2024-205390

Published: 2024

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood blood.2024025366.

https://doi.org/10.1182/blood.2024025366

Published: 2024

Includes: Supplemental data

Journal Articles

High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party

Blood (2023) 142 (Supplement 1): 4867.

https://doi.org/10.1182/blood-2023-187393

Published: 2023

Journal Articles

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Blood (2023) 142 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2023-177715

Published: 2023

Journal Articles

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Blood (2023) 142 (10): 865–877.

https://doi.org/10.1182/blood.2023020578

Published: 2023

Includes: Supplemental data

Journal Articles

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2021-151469

Published: 2021

Journal Articles

Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)

Yuntian Ding, Lei Wang, Ming Ni, Wenjie Gong, Sanmei Wang, Brigitte Neuber, Maria-Luisa Schubert, Tim Sauer, Angela Hückelhoven-Krauss, Thomas Luft, Ute Hegenbart, Stefan Schönland, Volker Eckstein, Jishi Wang, William Hermann Krüger, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt

Blood (2021) 138 (Supplement 1): 1810.

https://doi.org/10.1182/blood-2021-150106

Published: 2021

Journal Articles

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Maria-Luisa Schubert, Anita Schmitt, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, Birgit Michels, Philip Waldhoff, Leopold Sellner, Felix Korell, Susanne Hofmann, Petra Pavel, Anthony D Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt

Blood (2021) 138 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2021-152028

Published: 2021

Journal Articles

Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy

Felix Korell, Maria-Luisa Schubert, Tim Sauer, Anita Schmitt, Patrick Derigs, Tim Frederik Weber, Paul Schnitzler, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt

Blood (2021) 138 (Supplement 1): 4835.

https://doi.org/10.1182/blood-2021-149743

Published: 2021

Journal Articles

The Decrease of Anti-CD3 Antibody Concentration Improved the Cytotoxicity of Chimeric Antigen Receptor (CAR) T Cells in the Treatment of Chronic Lymphoblastic Leukemia (CLL)

Sanmei Wang, Yilian Yang, Yu Zhu, Lei Fan, Michael Schmitt, Maria Luisa Schubert, Jianyong Li

Blood (2021) 138 (Supplement 1): 4792.

https://doi.org/10.1182/blood-2021-150661

Published: 2021

Journal Articles

CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR

Nicola Schanda, Alexander Kunz, Tim Sauer, Maria-Luisa Schubert, Felix Korell, Angela Hückelhoven-Krauss, Brigitte Neuber, Mandy Hinkelbein, Carsten Müller-Tidow, Michael Schmitt, Anita Schmitt

Blood (2021) 138 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2021-152955

Published: 2021

Journal Articles

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Viktoria Blumenberg, MD, Maria-Luisa Schubert, MD, Eli Zamir, Sabine Schmidt, Roman Rohrbach, Philipp Waldhoff, Daria Bozic, Hendrik Pock, MD, Eran Elinav, Christian Schmidt, MD, Veit Buecklein, MD, Carsten Müller-Tidow, MD, Peter Dreger, MD, Michael von Bergwelt, MD PhD, Michael Schmitt, MD, Marion Subklewe, MD, Christoph Stein-Thöringer, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141210

Published: 2020

Journal Articles

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Maria-Luisa Schubert, MD, Anita Schmitt, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, MD, Ulrike Gern, Birgit Michels, Leopold Sellner, MD, Susanne Hofmann, MD, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 51.

https://doi.org/10.1182/blood-2019-125423

Published: 2019

Journal Articles

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Mingya Yang, MD, Lei Wang, MD, Ming Ni, Maria-Luisa Schubert, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Ruben A. Gößmann, Christian Kleist, Volker Eckstein, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 5620.

https://doi.org/10.1182/blood-2019-125622

Published: 2019

Journal Articles

Letermovir Prophylaxis Is Effective for Cytomegalovirus Reactivation after Allogeneic Hematopoietic Cell Transplantation: Single Center Real-World Data

Patrick Derigs, MD, Maria-Luisa Schubert, MD, Paul Schnitzler, PhD, Carsten Müller-Tidow, MD, Thomas Luft, MD PhD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 5650.

https://doi.org/10.1182/blood-2019-125675

Published: 2019

Journal Articles

PI3K Inhibition with Idelalisib for Optimized Production of Chimeric Antigen Receptor T Cells

Sophia Stock, Jean-Marc Hoffmann, Lei Wang, MD, Wenjie Gong, Angela Hückelhoven, PhD, Brigitte Neuber, PhD, Maria-Luisa Schubert, MD, Ulrike Gern, Anita Schmitt, MD, Carsten Müller-Tidow, Peter Dreger, MD, Michael Schmitt, MD PhD, Leopold Sellner, MD

Blood (2017) 130 (Supplement 1): 3194.

https://doi.org/10.1182/blood.V130.Suppl_1.3194.3194

Published: 2017

Journal Articles

Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells

Jean-Marc Hoffmann, Lei Wang, Angela Hückelhoven, PhD, Anita Schmitt, MD, Ulrike Gern, Leopold Sellner, MD, Christian Kleist, PhD, Jessica Wenthe, Patrick Wuchter, MD, Maria-Luisa Schubert, MD, Hyeon Joo Yoo, Ming Ni, Susanne Hofmann, MD, Peter Dreger, MD, Anthony D. Ho, MD, Angelica Loskog, PhD, Michael Schmitt, MD

Blood (2016) 128 (22): 3509.

https://doi.org/10.1182/blood.V128.22.3509.3509

Published: 2016

NARROW

Characterizing Environmental Adaption and Virulence of Gut Microbiome Enterococcus Spp. from Patients Receiving CD19-Targeted CAR-T Cell Therapy

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy

The Decrease of Anti-CD3 Antibody Concentration Improved the Cytotoxicity of Chimeric Antigen Receptor (CAR) T Cells in the Treatment of Chronic Lymphoblastic Leukemia (CLL)

CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Letermovir Prophylaxis Is Effective for Cytomegalovirus Reactivation after Allogeneic Hematopoietic Cell Transplantation: Single Center Real-World Data

PI3K Inhibition with Idelalisib for Optimized Production of Chimeric Antigen Receptor T Cells

Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only